Shares of Vaxart Inc. VXRT, -0.71% shot up 44% in premarket trade Thursday, after the biotechnology company announced results from a phase 2 trial that its oral flu vaccine performed better than Sanofi’s SNY, +0.09% SAN, -1.27% Fluzone. Sanofi’s U.S.-listed shares shed 1.6% ahead of the open. “These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%,” said Chief Scientific Officer Sean Tucker. Wouter Latour, chief executive of Vaxart, said, “We believe this clearly differentiates our oral vaccines from conventional injectable vaccines, and strongly suggests that vaccines based on Vaxart’s proprietary vector adjuvant system could be optimal to protect against mucosal pathogens, including some of the major public health threats such as flu, norovirus, RSV and many others.” The stock has tumbled 55.4% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF IBB, +0.74% has rallied 13.6% and the S&P 500 SPX, +0.07% has gained 9.4%.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.